

# Synergetic Photodynamic-Photothermal-Chemotherapy Dual Targeting Nanoplatfom Effective Against Breast Cancer in-Mice Model

Na Li<sup>1</sup>, Xiaochun Jiang<sup>2</sup>, Wanju Zhang<sup>1</sup>, Wenping Xiao<sup>1</sup>, Zhaona Wu<sup>1</sup>, Huirong Wang<sup>1</sup>, Feng He<sup>1</sup>

<sup>1</sup>Li Shizhen College of Traditional Chinese Medicine, Huanggang Normal University, Huanggang, 438000, People's Republic of China; <sup>2</sup>Hubei Key Laboratory for Processing and Application of Catalytic Materials, College of Chemistry and Chemical Engineering, Huanggang Normal University, Huanggang, 438000, People's Republic of China

Correspondence: Na Li; Feng He, Email ln19860622@126.com; hfeng@hust.edu.cn

**Introduction:** Combined multimodal therapy for breast cancer is a promising therapeutic approach to increase treatment efficacy and reduce systemic toxicity. The present study aimed to develop a novel multifunctional drug release nanoplatfom based on RGD-conjugated hyaluronic acid (HA)-functionalized copper sulfide (CuS) for activatable dual-targeted synergetic therapy against cancer.

**Methods:** The pH and NIR-responsive dual-targeting nanoplatfom CuS:Ce6@HA:DOX@RGD was prepared, characterized, and evaluated for its stability and photodynamic and photothermal properties. The loading and release of the drug were measured at different pH values with or without laser radiation using the dialysis method. The cellular uptake of the platform specifically by the tumor cells treated with different formulations was investigated through fluorescence imaging. The in vitro and in vivo biosafety levels were assessed systematically. Finally, the antitumor efficiencies against breast cancer were assessed via in vitro and in vivo experiments.

**Results:** The spheroid CuS:Ce6@HA:DOX@RGD exhibited remarkable stability and monodispersity in solution. The photosensitive CuS and Ce6 could simultaneously absorb the near-infrared light efficiently to convert NIR light to fatal heat and to generate reactive oxygen species. The CuS:Ce6@HA:DOX@RGD dissociated under an acid environment, causing the release of DOX into the tumor to accelerate upon laser irradiation. The CuS:Ce6@HA:DOX@RGD exhibited target-specific and strong binding ability via a synergic CD44/ $\alpha\beta_3$  receptor-mediated bimodal targeting, which led to improved therapeutic efficacy. The tumor growth was effectively inhibited using synergetic photodynamic/photothermal/chemo therapy. No evident systemic toxicity was noted during treatment.

**Conclusion:** The newly prepared CuS:Ce6@HA:DOX@RGD has great potential as an activatable theranostic nanoplatfom for efficient dual-targeted synergistic therapy against breast cancer.


**Keywords:** responsive nanoplatfom, targeting, drug delivery, synergistic therapy, breast cancer

## Introduction

Multifunctional nanoplatfoms for multimodal therapy have advanced greatly in recent years, which has improved the therapeutic efficiency against malignant tumors.

Currently, several therapeutic nanoplatfoms have been approved for cancer therapy, including liposomes, polymeric micelles, and albumin nanoparticles.<sup>1-4</sup> However, it is important to develop an efficient multifunctional nanoplatfom that exhibits high drug-loading efficiency, enhanced targeting and multiple therapeutic modalities. The nanoplatfom could realize effective delivery of drugs into the site of interest and specific targeting of tumors or other disease sites with an optimized therapeutic strategy and low side effect.<sup>5-7</sup> In this regard, a variety of stimuli-activatable nanoplatfoms capable of overcoming the above-stated issues have been developed.<sup>8-11</sup> An activatable nanoplatfom maintains an intact state and, therefore, does not affect the normal and healthy cells until its delivery to its target. However, with specific recognition or stimuli, these nanoplatfoms are activated. Moreover, the activatable nanoplatfom as drug delivery can induce controlled drug-release while being stimuli-responsive.<sup>12-15</sup> For instance, the near-infrared (NIR)-responsive

## Graphical Abstract



nanoplateform induces photothermal heating to directly destroy cancer cells, thereby remarkably improving the chemotherapeutic efficacy by triggering drug release.<sup>16–18</sup>

So far, several nanoplateforms with infrared absorption, such as carbon-based,<sup>19,20</sup> gold-based<sup>21,22</sup> and mesoporous silica-based nanoplateforms,<sup>23,24</sup> have been used as photothermal therapy agents. The copper sulfide (CuS) nanoparticles have gained particular interest in recent years owing to their high photothermal conversion efficiency, convenient preparation, low cost, good biodegradability, low cytotoxicity, and excellent photoelectric properties.<sup>25–29</sup> The modification of bovine serum albumin (BSA) on CuS results in ultrasmall biosafe CuS-BSA nanoparticles, which exhibit promoted drug loading capacity. Moreover, CuS-BSA may be loaded with a photosensitive reagent (chlorin e6, Ce6), generating a multifunctional nanoplateform CuS:Ce6 for combined photodynamic and photothermal therapy (PDT/PTT). Importantly, the surface decoration of CuS:Ce6 is highly desirable for the construction of tumor-targeted and stimuli-responsive drug delivery systems. Hyaluronic acid (HA) has been used widely for fabricating drug delivery systems owing to its biodegradable and non-toxic nature. HA-based nanoplateforms serve as activatable delivery system for high drug loading and exhibit a pH-responsive and heat-responsive switch.<sup>30–32</sup> HA shell is able to be degraded by hyaluronidase to trigger drug release in cells.<sup>31</sup> Moreover, HA as a powerful targeting moiety binds specifically to the cluster determinant 44 (CD44) receptor, which is overexpressed on cancer cells.<sup>33,34</sup> In addition, HA with multiple functional groups may be modified with target molecules (RGD) and then loaded with chemotherapeutic drug (doxorubicin, DOX). In order to enhance interaction with the surface receptors on cancer cells, the surface of an HA-based delivery systems is decorated with the RGD for constructing dual-targeted drug delivery systems. According to the author's knowledge, few studies have reported the construction of HA-coated CuS for multimodal therapy against cancer. Therefore, it is of significance to design tumor-targeted and activatable multifunctional nanoplateforms, using simple and mild methods for facilitating photodynamic and photothermal therapy plus chemotherapy (PDT/PTT/Chemo) to provide accurate and optimized therapy against cancer.

In this context, a novel multifunctional therapeutic system based on CuS:Ce6@HA:DOX@RGD nanoplateform was constructed to co-encapsulate chemo-drug doxorubicin (DOX) and photosensitizer (Ce6) for multimodality treatment. The physicochemical properties of the established nanoplateform were investigated. The results revealed that the CuS:Ce6@HA:DOX@RGD could specifically target CD44 and bind to the  $\alpha v \beta 3$  integrin receptors,<sup>35</sup> which are overexpressed in tumor cells and tumor stroma, thus achieving enhanced tumor-targeted drug delivery. The cellular uptake and targeting ability of CuS:Ce6@HA:DOX@RGD were evaluated in MCF-7 cells. Upon irradiation with NIR laser, the Ce6 and CuS in the CuS:Ce6@HA:DOX@RGD generated substantial ROS and heat, respectively, to fully release DOX for suppressing tumor growth in combination with PDT/PTT/Chemo. The *in vitro/vivo* biosafety levels and therapeutic effects were then evaluated systematically.

## Materials and Methods

Copper(II) chloride dihydrate ( $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ ), sodium sulfide nonahydrate ( $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$ ) and Sodium hyaluronic acid (HA) were obtained from Beijing lark technology co., Ltd. (Beijing, China). Bovine Serum Albumin (BSA) was purchased from Sigma Aldrich (St. Louis, MO, USA). Chlorin e6 (Ce6), Doxorubicin (DOX), 4, 6-diamidino-2-phenylindole (DAPI) and Calcein-AM were obtained from Beijing lark technology co., Ltd. (Beijing, China). RGD was bought from China Peptides Co., Ltd. (Shanghai, China). 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC), N-Hydroxy-sulfosuccin-imide (Sulfo-NHS), 2,7-dichlorofluorescein diacetate (DCFH-DA), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human breast cancer MCF-7 cells were acquired by Fuzhou University. Female mice (Balb/c, weighing ~20 g, 4 weeks old) were obtained from the Laboratory Animal Center of Wuhan Servicebio Biology Technology Co., Ltd. Ultrapure water ( $18.2 \text{ M}\Omega \cdot \text{cm}$ ) was used throughout the entire experiments.

### The Preparation of CuS and CuS:Ce6

According to previous reports, CuS was prepared with slightly modification.<sup>25</sup> Briefly, a  $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$  solution (0.1 mmol, 10 mL) was mixed with a BSA solution (50 mg/mL, 10 mL) and stirred at 37 °C for 0.5 h. After the reaction, a NaOH solution was dipped into the above mixture. Subsequently, a  $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$  solution (242.16 mg/mL, 0.8 mL) was added to the above solution and stirred for 8 h. Then, the solution were dialyzed and dried to obtain the final product. BSA was conjugated with Ce6 by EDC and Sulfo-NHS in DMSO. The CuS:Ce6 was prepared following the same procedure as above.

### The Synthesis of CuS:Ce6@HA:DOX@RGD

First, a mixture of CuS:Ce6 (1.0 mg) and HA (10.0 mg) in Tris-HCl solution buffer was stirred at room temperature for 24 h. The obtained CuS:Ce6@HA was dialyzed in PBS solution (pH 7.4). Then, EDC (20 mg) and Sulfo-NHS (20 mg) dissolved in anhydrous DMF (1 mL) were added to the above solution and reacted at room temperature for 30 min under stirring slowly. Next, 1.0 mL of RGD (1 mg/mL) solution were added and stirred overnight at room temperature. Then, the obtained CuS:Ce6@HA@RGD were dialyzed for 24 h. The CuS:Ce6@HA@RGD loaded with DOX was prepared by mixing equal amounts of DOX (2.5 mg/mL) and CuS:Ce6@HA@RGD, and the mixture was then stirred for 24 h at room temperature in the dark. The resulting mixture was dialyzed for 24 h and centrifuged. The products were designated as CuS:Ce6@HA:DOX@RGD.

## Characterization

The morphology and elemental composition of nanoparticles were characterized by a transmission electron microscopy (TEM, JEM-2010FEF, Japan). The particle sizes were tested by Dynamic Light Scattering (DLS, Mastersizer 3000, England). Zeta potentials were measured on a Malvern Zeta sizer-Nano Z instrument. The UV-vis-NIR absorption spectra were recorded on UV3600i plus spectrophotometer (Shimadzu, Japan). The Fluorescence spectra were recorded with a fluorescence spectrophotometer (Edinburgh FLS920, England). Thermal images of solutions were obtained by a Fluke infrared thermal camera. The FL images were obtained on Nikon inverted DM4000 M fluorescence microscope and Olympus FV3000 confocal laser scanning microscope. The amount of Ce6 and DOX was respectively measured with a Nicolet Evolution 300 ultraviolet-visible (UV-vis) spectrometer at 395 and 480 nm.

## Stability

The CuS:Ce6@HA:DOX@RGD were dispersed into serum, cell culture medium, and PBS (pH 7.4) at 37 °C within a week. At preset time points, the particle sizes of CuS:Ce6@HA:DOX@RGD were monitored by DLS to investigate the stability. Meantime, the suspension was exposed to NIR irradiation ( $1.5 \text{ W/cm}^2$ ) to investigate its photostability.

## Detection of Photodynamic and Photothermal Ability

DCFH-DA was used as a chemical probe to detect the generation of ROS.<sup>36</sup> The DCFH-DA was respectively added into 2 mL of PBS, Ce6 and CuS:Ce6@HA:DOX@RGD solution in the dark. Then, the mixture was irradiated with 663 nm laser ( $1.5 \text{ W/cm}^2$ ) for different times (0, 1, 3, 6, 10, and 15 min), respectively. After irradiation, the fluorescence spectra of DCF at 522 nm were tested to evaluate the generation of ROS. The CuS:Ce6@HA:DOX@RGD were incubated cells and then washed with PBS. DCFH-DA was added and then washed after incubation for 30 min. After laser radiation, the fluorescence intensity at 522 nm was determined using a fluorescence spectrophotometer. Control group was not treated, and the CuS:Ce6@HA:DOX@RGD group was not illuminated with a laser. The aqueous solutions of CuS and CuS:Ce6@HA:DOX@RGD were irradiated with a 980 nm laser at  $1.5 \text{ W/cm}^2$  for 6 min. During the irradiation, the temperature was recorded at 0, 1, 2, 3, 4, 5, and 6 min. The corresponding thermal images at 0, 1, 2, 3, 4, 5, and 6 min were acquired by an infrared thermal camera. The CuS:Ce6@HA:DOX@RGD solution at a series of concentrations (25, 50, 100, 150, and 200  $\mu\text{g/mL}$ ) were exposed to 980 nm laser at  $1.5 \text{ W/cm}^2$  for 6 min. The CuS:Ce6@HA:DOX@RGD solution under 980 nm irradiation with various power densities (0.5, 0.75, 1.0, and  $1.5 \text{ W/cm}^2$ ) were also monitored. The photothermal stability of CuS:Ce6@HA:DOX@RGD was evaluated by on/off-cycle irradiation experiment.

## In vitro pH/NIR-Responsive Evaluation

To investigate the pH/NIR-responsive DOX release, the CuS:Ce6@HA:DOX@RGD solution were transferred into the dialysis bag, which were dialyzed in different pH conditions (pH 7.4, 6.0, and 5.0) in the presence and absence of hyaluronidase (HY), respectively. Also, we assessed the effect of NIR irradiation on the release behavior of DOX. At selected time points, 1 mL of the release medium was collected and replaced with the same fresh buffered solution. Subsequently, the released DOX was quantified by a UV-vis spectrometer. Moreover, the fluorescence recovery was examined in pH 5.0 without and with 980 nm laser. The fluorescence changes of released DOX were monitored.

## Cell Uptake and Intracellular DOX Release

MCF-7 cells and normal cells were respectively seeded into 6-well plate at a density of  $1 \times 10^4$  cells and incubated for 12 h. Then, DOX, CuS:Ce6@HA:DOX and CuS:Ce6@HA:DOX@RGD were respectively cultured with MCF-7 cells for 4 h. Similarly, the CuS:Ce6@HA:DOX@RGD were cultured with normal cells for 4 h. For competitive binding test, the MCF-7 cells were pretreated with a large excess of HA, RGD and HA plus RGD for 2 h, respectively. Subsequently, the CuS:Ce6@HA:DOX and CuS:Ce6@HA:DOX@RGD were added and incubated for 2 h, respectively. To evaluate the cellular pH/NIR-responsive DOX release, MCF-7 cells were respectively incubated for 1, 2 and 4 h with and without laser radiation. Afterward, all cells were observed and fluorescent images were recorded by a fluorescence microscope. To quantitatively measure the cellular uptake and DOX release, MCF-7 cells were washed and lysed after different treatments. Next, the supernatant was collected by centrifugation. The fluorescence intensity of DOX was determined using a fluorescence spectrophotometer.

## In vitro Therapeutic Effect with Laser

The synergistic effect of PDT/PTT/Chemo in MCF-7 cells was assessed by MTT assay and calcein AM/PI staining. MCF-7 cells were incubated 4 h with PBS (pH=7.4) and CuS:Ce6@HA:DOX@RGD, respectively. The cells were divided into seven groups: (a) control (treated with PBS) without laser; (b) control (PBS) + NIR; (c) CuS:Ce6@HA:DOX@RGD; (d) CuS:Ce6@HA:DOX@RGD+663 nm; (e) CuS:Ce6@HA:DOX@RGD+980 nm; (f) CuS:Ce6@HA@RGD+663 nm+980 nm; (g) CuS:Ce6@HA:DOX@RGD+663 nm+980 nm. After 12 h, the cells were rinsed with PBS. The cell viability was tested by MTT assay. The dead/live cells were also stained with calcein-AM/PI and imaged by fluorescence microscope. MCF-7 cells were incubated with different concentrations of CuS:Ce6@HA:DOX@RGD for 4 h and then divided into four groups: (a) without laser; (b) with 663 nm; (c) with 980 nm; (d) with 663 and 980 nm. The cells were incubated for another 12 h. The MTT assay was performed to test cell viability.



## In vivo Antitumor Evaluation

The tumor-bearing mice were randomly divided into six groups as follow ( $n = 5$  in each group): (a) control (treated with PBS) without laser; (b) control (PBS) + NIR; (c) CuS:Ce6@HA:DOX@RGD (1.5 mg/kg); (d) CuS:Ce6@HA:DOX@RGD (1.5 mg/kg)+663 nm; (e) CuS:Ce6@HA:DOX@RGD (1.5 mg/kg)+980 nm; (f) CuS:Ce6@HA:DOX@RGD (1.5 mg/kg)+663 nm+980 nm. All groups of mice were intravenously injected with the same volume (200  $\mu$ L). The tumors sites in irradiation groups were irradiated with 1.5 W/cm<sup>2</sup>. The tumor size and body weight of each mice were measured every two days. All mice were sacrificed after 14 days. The tumors were harvested for weighting, photo imaging, hematoxylin and eosin (H&E) staining. The tumor growth inhibition rate was estimated using the following formula: Inhibition % =  $(1 - M_{\text{treated group}} / M_{\text{control group}}) \times 100\%$ , where  $M_{\text{treated group}}$  and  $M_{\text{control group}}$  were the average tumor weights. Ultimately, major organs (liver, kidney, spleen, heart, and lung) of mice from the six groups were harvested for histological examination.


## Biosafety Assessment

For in vitro toxicity assessment, various concentrations of CuS:Ce6@HA:DOX@RGD (0, 12.5, 25, 50, 100 and 200  $\mu$ g/mL) were incubated with normal cells for 12 or 24 h, respectively. MTT assay was executed to measure cell viability. Meanwhile, the cell viability was also determined by a standard calcein-AM/PI live/dead assay. The fluorescence images of the cells were captured by fluorescence microscope. A standard hemolysis test was performed to evaluate blood compatibility of CuS:Ce6@HA:DOX@RGD. Briefly, the collected blood was washed with saline and centrifuged. The diluted red cell suspension was respectively mixed with CuS:Ce6@HA:DOX@RGD with various concentration. Deionized H<sub>2</sub>O and PBS were used as a positive or negative control, respectively. The absorbance of each group was then measured at 540 nm. The hemolysis percentage was calculated as the following formula: Hemolysis% =  $(\text{Sample absorbance} - \text{negative control absorbance}) / (\text{positive control absorbance} - \text{negative control absorbance}) \times 100\%$ .

To assess in vivo toxicity, the healthy Balb/c mice were respectively intravenously injected with PBS or Ce6@HA:DOX@RGD (1.5 mg/kg). The body weights of mice were monitored for 14 days after treatment. At the desired time point, blood was drawn for serum biochemistry assay and routine blood analysis.

## Results and Discussion


The morphologies of CuS:Ce6 and CuS:Ce6@HA:DOX@RGD were characterized through TEM, and the results are presented in Figure 1A and B, respectively. The TEM images revealed that the nanoparticles displayed excellent dispersity and The mean size of CuS:Ce6@HA:DOX@RGD (~ 20 nm) was much larger than that of CuS:Ce6 (~ 8 nm) due to the coating of HA. The average hydrodynamic diameters were measured using DLS. As depicted in Figure 1C, there was a slight increase in the hydrodynamic diameter was observed compared to the diameter in the TEM image, which was attributed to the adequate number of carboxyl groups in CuS:Ce6 and the adorned RGD molecule in CuS:Ce6@HA:DOX@RGD. The zeta potential change (Figure 1D) of the nanoparticles was within the range from -15 mV to -29 mV, which might be attributed to a dynamic self-assembly process of the nanoparticles. The results of the EDS analysis depicted in Figure 1E revealed that CuS:Ce6@HA:DOX@RGD was composed of Cu, S, C, N, and O elements. Moreover, the elemental mapping images (Figure 1F) showed that the signals of Cu, S, C, N, and O were dispersed homogeneously across the selected area of the CuS:Ce6@HA:DOX@RGD sample. The optical properties were then studied using UV-vis-NIR spectroscopy. As illustrated in Figure 1G, the CuS:Ce6@HA:DOX@RGD exhibited a significant characteristic absorption peak of CuS at 980 nm. Subsequently, the drug-loading efficiency of the nanoparticles was determined using ultraviolet spectroscopy. The CuS:Ce6@HA:DOX@RGD exhibited a high drug-loading efficiency (13.6 wt % for Ce6 and 14.5 wt % for DOX), which enabled adequate co-delivery of the photosensitizer and the chemotherapeutic agent. In addition, the negligible changes were observed in HD, which indicated that CuS:Ce6@HA:DOX@RGD had excellent colloidal stability after one week of storage even under laser irradiation (Figure 1H and I). Collectively, these results demonstrated that CuS:Ce6@HA:DOX@RGD nanoparticles with excellent stability had been prepared successfully and could be used in subsequent experiments.



**Figure 1** TEM images of CuS:Ce6@BSA (A) and CuS:Ce6@HA:DOX@RGD (B). (C) Size distribution of CuS:Ce6@BSA and CuS:Ce6@HA:DOX@RGD. (D) Zeta potentials of CuS:Ce6@BSA, CuS:Ce6@HA, CuS:Ce6@HA@RGD, and CuS:Ce6@HA:DOX@RGD. (E) EDS of the CuS:Ce6@HA:DOX@RGD. (F) Elemental mapping images of the CuS:Ce6@HA:DOX@RGD. (G) UV-vis-NIR absorbance spectra of CuS and CuS:Ce6@HA:DOX@RGD. (H) Hydrodynamic diameters (HD) measurement of the CuS:Ce6@HA:DOX@RGD in PBS and DMEM. (I) Hydrodynamic diameters (HD) measurement of the CuS:Ce6@HA:DOX@RGD in PBS and DMEM with laser irradiation.

To assess photodynamic performance of CuS:Ce6@HA:DOX@RGD, the ROS levels were investigated with a probe (DCFH-DA), an indicator that ROS can rapidly oxidize it to emit fluorescence at 522 nm. The generated ROS levels were assessed based on the changes of the fluorescence at 522 nm. The fluorescence signal was observed, as depicted in Figure 2A and B, upon laser irradiation. Moreover, the fluorescence intensity changes were recorded at 522 nm, and the

results are presented in Figure 2C. No significant change was detected in PBS (control group) with 15 min of laser irradiation. However, the intensity of the fluorescence emitted from the Ce6 and CuS:Ce6@HA:DOX@RGD solutions apparently increased with the increase in the duration of irradiation. As shown in Figure 2D, a high amount of ROS was generated according to the strong fluorescent intensity at 522 nm in CuS:Ce6@HA:DOX@RGD-treated cells after laser




**Figure 2** DFC fluorescence spectra of Ce6 (A), and CuS:Ce6@HA:DOX@RGD (B) upon 663 nm laser irradiation. (C) The DFC fluorescence intensity at 522 nm in PBS, Ce6 and CuS:Ce6@HA:DOX@RGD as a function of irradiation time. (D) The intracellular DFC fluorescence intensity at 522 nm after different treatments. (E) Temperature change curve of CuS:Ce6@HA:DOX@RGD, CuS, and PBS with 980 nm laser irradiation. (F) Photothermal stability of CuS:Ce6@HA:DOX@RGD. (G) Real-time thermal imaging of CuS (a), and CuS:Ce6@HA:DOX@RGD (b) solution upon laser irradiation. (H) Temperature increase curves of CuS:Ce6@HA:DOX@RGD at various concentrations during NIR irradiation. (I) Temperature increase curves of CuS:Ce6@HA:DOX@RGD under various power densities.

irradiation. These results illuminated that CuS:Ce6@HA:DOX@RGD could produce enough ROS to result in cellular toxicity. In view of the broad absorbance in the near-infrared region of CuS, the photothermal conversion of CuS:Ce6@HA:DOX@RGD in aqueous solution was evaluated under continuous laser irradiation at 980 nm and 1.5 W/cm<sup>2</sup> for 6 min. As depicted in Figure 2E, the temperature of both CuS and CuS:Ce6@HA:DOX@RGD respectively increased by approximately 30°C within 6 min, while no evident temperature change was observed for the PBS solution (control group). These results demonstrated that when using laser irradiation at 1.5 W/cm<sup>2</sup> for 6 min, the temperature was sufficiently high to kill cancer cells. The temperature elevation curve after four cycles of heating and natural cooling is depicted in Figure 2F, which illustrates that the excellent photothermal stability of the CuS:Ce6@HA:DOX@RGD. The real-time thermal images captured during the NIR laser irradiation are presented in Figure 2G. Furthermore, CuS:Ce6@HA:DOX@RGD exhibited remarkable photothermal performance that was dependent on concentration and laser irradiation power density-dependent photothermal performance (Figure 2H and I). These results indicated that the potential of the CuS:Ce6@HA:DOX@RGD has the potential as an activatable PDT/PTT agent for killing cancer cells.


Responsiveness of CuS:Ce6@HA:DOX@RGD to pH change and NIR irradiation was monitored in a release medium. As shown in Figure 3A, in the presence of hyaluronidase, the cumulative release of DOX reached 51.8% at pH 5.0 without laser irradiation, obviously higher than that without hyaluronidase (26.2% at pH 5.0). In contrast, a negligible release was detected at pH 7.4. The main reason is that hyaluronidase had higher enzymatic activity to degrade HA shell under acidic conditions than in neutral environment, which allowed some of the DOX to be released from the carrier, in agreement with a previous report.<sup>31</sup> Therefore, the pH-induced DOX release could prevent DOX release in blood circulation as the tumor tissue had an acidic pH lower than the normal tissue and biological fluids.<sup>37,38</sup> On the other hand, the DOX release profile from the CuS:Ce6@HA:DOX@RGD was about 58.2% at pH 5.0 with hyaluronidase and NIR laser, which was more than that of 51.8% with hyaluronidase and without NIR laser. The produced photothermal effect loosened the structure of the HA layer and decreased the viscosity of local HA,<sup>39,40</sup> thereby accelerating the release of DOX into the external environment. As expected, irradiation with NIR laser and a mildly acidic environment could induced the degradation of CuS:Ce6@HA:DOX@RGD and the release of DOX. It is noteworthy that the fluorescent signals of DOX were almost entirely quenched after DOX was loaded onto CuS:Ce6@HA@RGD, resulting in a fluorescence switch-off, due to the quenching ability of CuS based on Förster resonance energy transfer (FRET).<sup>41,42</sup> As illustrated in Figure 3B, at pH 5.0 and laser irradiation, the fluorescence intensity increased. The pH/NIR-induced DOX release led to DOX fluorescence switch-on. Collectively, these results demonstrated that the CuS:Ce6@HA:DOX@RGD exhibited pH-induced and NIR laser-responsive DOX release propensity, which would facilitate improving the efficiency of antitumor therapy.

We then studied the tumor selectivity of CuS:Ce6@HA:DOX@RGD in MCF-7 cells. The ability of CuS:Ce6@HA:DOX@RGD to target tumor cell was evaluated using fluorescence imaging. As illustrated in Figure 4A, the MCF-7 cells exhibited an extremely weak fluorescence signal in the DOX group, due to nonspecific uptake. The MCF-7 cells treated with CuS:Ce6@HA:DOX exhibited higher fluorescence signals compared to that of the cells treated with DOX, which was attributed due to



**Figure 3 (A)** In vitro cumulative release profile of DOX from CuS:Ce6@HA:DOX@RGD without NIR laser irradiation in different pH (a: pH 5.0, b: pH 6.0, c: pH 7.4) and with hyaluronidase in different pH (d: pH 5.0, e: pH 6.0, f: pH 7.4) and in different pH (g: pH 5.0, h: pH 6.0, i: pH 7.4) with NIR laser irradiation and hyaluronidase. **(B)** Fluorescence signal recovery of CuS:Ce6@HA:DOX@RGD at pH 5.0 without or with irradiation at indicated time points.






**Figure 4** (A) Cellular uptake of DOX, CuS:Ce6@HA:DOX, CuS:Ce6@HA:DOX@RGD, CuS:Ce6@HA:DOX+HA, CuS:Ce6@HA:DOX@RGD+RGD, and CuS:Ce6@HA:DOX@RGD+ HA+ RGD. C refers to cancer cell. N refers to normal cell. (B) Corresponding intracellular mean fluorescence intensity. (C) Cellular uptake of CuS:Ce6@HA:DOX@RGD after culture for 1, 2 and 4 h with or without laser irradiation. (D) Corresponding intracellular mean fluorescence intensity after incubation for 1, 2 and 4 h with or without laser irradiation.

the ability to bind specifically with the CD44 receptors overexpressed on the surface of cancer cells. However, the fluorescence signals were evidently higher in the CuS:Ce6@HA:DOX@RGD group compared to the CuS:Ce6@HA:DOX group. The fluorescence signals of CuS:Ce6@HA:DOX@RGD in normal cells presented low cellular uptake. These findings indicated that the specific and strong target-binding ability was due to synergic CD44/ $\alpha v \beta 3$  receptor-mediated bimodal targeting. In addition, the competitive binding of HA/RGD was studied to investigate the binding specificity of CuS:Ce6@HA:DOX@RGD (Figure 4A). Free HA/RGD was incubated with MCF-7 cells followed by the addition of CuS:Ce6@HA:DOX@RGD, allowing the receptors on the cells to be blocked by free HA/RGD. Indeed, the cellular uptake of CuS:Ce6@HA:DOX@RGD decreased evidently, confirming that the HA and RGD components in CuS:Ce6@HA:DOX@RGD conferred it with the dual-targeting. Meanwhile, the mean fluorescence intensity of the cells incubated with CuS:Ce6@HA:DOX@RGD was the highest among the different treatment groups (Figure 4B), which further confirmed the dual-mode tumor-targeting ability. In order to determine whether the local hyperthermia produced upon laser irradiation would accelerate the release of the loaded DOX specifically into the tumor tissue, the MCF-7 cells were respectively incubated with CuS:Ce6@HA:DOX@RGD with or without laser irradiation.



As depicted in Figure 4C, the fluorescence signals of DOX were enhanced upon laser treatment as compared to the signals from non-irradiated cells. The accelerated DOX release after internalization was also confirmed based on the quantified fluorescence intensity (Figure 4D). These findings highlighted that the CuS:Ce6@HA:DOX@RGD was efficiently internalized by cancer cells and enhanced the intracellular release of DOX.

Cytotoxicity assay was employed to reveal the synergistic antitumour effects of CuS:Ce6@HA:DOX@RGD in MCF-7 cells by the detection of MTT test and live/dead cells staining assays. As depicted in Figure 5A, the CuS:Ce6@HA:DOX@RGD group with two rounds of irradiation exhibited a further powerful cancer cell-killing efficacy compared to the CuS:Ce6@HA:DOX@RGD group with one just round of irradiation and the CuS:Ce6@HA@RGD group with two rounds of irradiation, suggesting a good synergistic therapeutic effect. The cell viability decreased slightly in the CuS:




**Figure 5** (A) Viabilities of MCF-7 cells after different treatments: control(a), 663 nm+980 nm laser(b), CuS:Ce6@HA:DOX@RGD(c), CuS:Ce6@HA:DOX@RGD+663 nm(d), CuS:Ce6@HA:DOX@RGD+980 nm(e), CuS:Ce6@HA@RGD+663 nm+980 nm(f), and CuS:Ce6@HA:DOX@RGD+663 nm+980 nm(g). (B) Live/dead images of MCF-7 cells stained with calcein AM/PI under different conditions. (C) Viabilities of MCF-7 cells incubated with different concentrations of CuS:Ce6@HA:DOX@RGD without laser irradiation(a), with 663 nm(b), with 980 nm(c), and with 663 nm+980 nm(d) laser irradiation.

Ce6@HA:DOX@RGD group, while the control and only laser treatment groups exhibited negligible toxicity in MCF-7 cells. The results of the subsequent live/dead cell-staining experiments (Figure 5B) revealed the MCF-7 cells stained with PI (dead cells) and calcein-AM (live cells) in different groups. The MCF-7 cells in the CuS:Ce6@HA:DOX@RGD group with two rounds of irradiation exhibited evidently higher killing rates compared to the other five groups. The overall variation trend of the fluorescence pattern was consistent with the MTT results. In addition, the viability of MCF-7 cells decreased greatly as the concentration of CuS:Ce6@HA:DOX@RGD increased (Figure 5C), demonstrating dose-dependent apoptosis upon laser irradiation. Collectively, these results demonstrated that the CuS:Ce6@HA:DOX@RGD group with two rounds of irradiation exhibited a synergistic PDT/PTT/Chemo effect that enhanced the efficiency of killing cancer cells.

Encouraged by the high cytotoxicity of CuS:Ce6@HA:DOX@RGD *in vitro*, we further evaluated the PDT/PTT/Chemo therapeutic efficiency in tumor-bearing mice model. The tumor-bearing mice were divided into six groups and then treated followed by an assessment of the variation trend of tumor volume in the next 14 days. In addition, the relative tumor growth curve was obtained for each group and is depicted in Figure 6A. Notably, the tumor growth in the CuS:Ce6@HA:DOX@RGD group with rounds of irradiation presented the greatest inhibition, owing to the synergetic PDT/PTT/Chemo effect. The CuS:Ce6@HA:DOX@RGD groups with just one round of irradiation presented moderate tumor inhibition due to PDT/Chemo and PTT/Chemo effects. The CuS:Ce6@HA:DOX@RGD group without irradiation presented limited tumor inhibition due to the single Chemo effect. In contrast, the tumor volume in groups a and b increased significantly over the course of treatment. Meanwhile, the body weight of the mice in each group was recorded (Figure 6B) during the therapeutic process, and insignificant body weight changes were observed. After treatments for 14 days, the mice were sacrificed (following standard and allowed practices), and the tumors were excised, imaged, weighed, and subjected to further analysis using H&E staining. As depicted in Figure 6C-E, the smallest tumors and the lowest tumor mass were observed in the CuS:Ce6@HA:DOX@RGD group with two rounds of irradiation. The tumor growth inhibition rate reached 90.3% in this group, which was much higher than that noted in the other five groups. Furthermore, the H&E staining results revealed that the CuS:Ce6@HA:DOX@RGD group with two rounds of irradiation presented the most severe morphological changes and necrosis (Figure 6F). Collectively, these results indicated that the tumor growth could be effectively inhibited through the synergetic PDT/PTT/Chemo effect.


It is well recognized that good biocompatibility/biosafety is essential for the application of the prepared CuS:Ce6@HA:DOX@RGD in the field of biomedicine. Therefore, the *in vitro/in vivo* biocompatibilities of CuS:Ce6@HA:DOX@RGD were evaluated systematically using normal cell culture, the hemolysis assay, and whole animal experiments. As depicted in Figure 7A and B, after co-incubation with normal cells at increasing concentrations for 12 h or 24 h followed by the MTT assay indicated that both the cell viabilities remained above 85% at the different concentrations of CuS:Ce6@HA:DOX@RGD (up to 200  $\mu\text{g/mL}$ ). Meanwhile, the *in vitro* cytotoxicity of CuS:Ce6@HA:DOX@RGD was also evaluated using the calcein-AM/PI (live/dead) staining assay. After incubation for 12 h or 24 h, numerous living cells with green fluorescence and only a few dead cells with red fluorescence were observed (Figure 7C). The results of the live/dead cell-staining assay were, therefore, consistent with the MTT results, demonstrating negligible cell toxicity. The biocompatibility was further confirmed using the hemolysis assay. The results revealed no apparent hemolysis in the treated group within the experimental concentration range (Figure 7D). The hemolysis ratio, in the range of experimental concentrations, was less than 5%.

After injecting the CuS:Ce6@HA:DOX@RGD solution intravenously into healthy mice, no evident body weight decrease (Figure 7E) was observed compared to the mice in PBS group. Subsequently, a blood routine analysis was conducted (including RBC, HGB, WBC, and PLT) to investigate the potential toxicity of CuS:Ce6@HA:DOX@RGD in blood cells and the hematopoietic system. As depicted in Figure 8, no significant abnormalities were observed between the treatment and control groups after administration for 1 days, 7 days, and 14 days. In addition, the blood biochemistry evaluations, including ALB, AST, and ALT, CR and UREA, revealed no evident abnormal changes were observed after administration for 1 days, 7 days, and 14 days (Figure 8). Furthermore, the H&E staining images of the major organs (liver, kidney, spleen, heart, and lung) of the mice in the treated groups were obtained and are presented in Figure 9. No evident tissue abnormalities were observed after administration for 14 days. These results collectively demonstrated the safety of CuS:Ce6@HA:DOX@RGD for application in anticancer.




**Figure 6** (A) Relative tumor growth curves and (B) the variations of body weight in different groups: (a) control (treated with PBS), (b) control (PBS) + NIR, (c) CuS:Ce6@HA:DOX@RGD, (d) CuS:Ce6@HA:DOX@RGD+663nm, (e) CuS:Ce6@HA:DOX@RGD+980nm; (f) CuS:Ce6@HA:DOX@RGD+663nm+980nm. (C) Photographs of tumors collected from various mice groups after 14 day treatment. (D) Average tumor weight of each group. (E) Tumor inhibition rate of each group. (F) H&E-stained images of tumor tissues section from different groups. \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ .





**Figure 7** Cell viability after incubation with CuS:Ce6@HA:DOX@RGD at different concentrations for 12 h (A) and 24 h (B). (C) Fluorescence images of cells stained with calcium-AM and PI under different conditions. (D) Hemolysis analysis of CuS:Ce6@HA:DOX@RGD at various concentrations, using PBS and deionized water as a negative and positive control, respectively. (E) The body weights curves of mice after different treatments.




**Figure 8** In vivo toxicology assessment by the routine blood analysis: white blood cell (WBC), red blood cell (RBC), hematocrit (HCT), hemoglobin (HGB), platelet (PLT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC); the blood biochemistry test: alanine transaminase (ALT), Aspartate transaminase (AST), albumin (ALB), lactic dehydrogenase (LDH), total protein (TP), total bilirubin (TBIL), urea (UA), and creatinine (CREA).

## Conclusion

In the present study, a novel biodegradable nanoplatform named CuS:Ce6@HA:DOX@RGD was fabricated successfully using a facile and green approach. We have demonstrated that the cellular uptake of the CuS:Ce6@HA:DOX@RGD can be improved by CD44/ $\alpha\beta$ 3-mediated endocytosis. The dual-targeting CuS:Ce6@HA:DOX@RGD possessed excellent biocompatibility and exhibited dual-responsive pH and NIR irradiation DOX release and high photodynamic and photothermal effects. As the result of high cellular internalization and pH/NIR response capability, the CuS:Ce6@HA:DOX@RGD exhibited high cytotoxicity against MCF-7 cancer cells and significant antitumor effect in vivo. Our results demonstrate that CuS:Ce6@HA:DOX@RGD possess great potential for dual-targeting and dual-responsive synergistic therapy and the nanoplatform is expected to serve as a good platform for carrying other therapeutic agents to the micro-





**Figure 9** H&E-stained images of tissues (liver, kidney, spleen, heart, and lung) of the mice harvested from various mice groups (a: control, b: 663nm+980nm, c: CuS:Ce6@HA:DOX@RGD, d: CuS:Ce6@HA:DOX@RGD+663nm, e: CuS:Ce6@HA:DOX@RGD+980nm; f: CuS:Ce6@HA:DOX@RGD+663nm+980nm) after 14 day treatment.



environment of tumour. The findings of the present study provided a novel strategy to design an effective and multifunctional nanoplatform exhibiting enhanced therapeutic efficacy against cancer.

## Ethics Approval

All animal and MCF-7 cell procedures were performed in strict accordance with the Guidelines for the Care and Use of Laboratory Animals and approved by the Animal Ethics Committee of Huanggang Normal University.

## Funding

This work was financially supported by the National Natural Science Foundation of China (21765022), the Research Fund of Huanggang Normal University (2042023016), and the Key Research and Development Program of Hubei Province (2022BCE013).

## Disclosure

The authors declare no competing interest in this work.

## References

1. Zhang M, Wang W, Wu F, et al. Biodegradable poly ( $\gamma$ -glutamic acid)@glucose oxidase@carbon dot nanoparticles for simultaneous multimodal imaging and synergetic cancer therapy. *Biomaterials*. 2020;252:120106. doi:10.1016/j.biomaterials.2020.120106
2. Xie Q, Gao S, Tian R, et al. Enzyme and reactive oxygen species-responsive dual-drug delivery nanocomplex for tumor chemo-photodynamic therapy. *Int J Nanomed*. 2023;18:1–16. doi:10.2147/IJN.S393862
3. Yang G, Phua SZF, Lim WQ, et al. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy. *Adv Mater*. 2019;31:1901513. doi:10.1002/adma.201901513
4. Ma Q, Zhao Y, Guan Q, et al. Amphiphilic block polymer-based self-assembly of high payload nanoparticles for efficient combinatorial chemo-photodynamic therapy. *Drug Deliv*. 2020;27(1):1656–1666. doi:10.1080/10717544.2020.1850921
5. Chen GY, Roy I, Yang CH, et al. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. *Chem Rev*. 2016;116(5):2826–2885. doi:10.1021/acs.chemrev.5b00148
6. Shanmugam M, Kuthala N, Vankayala R, et al. Multifunctional CuO/Cu<sub>2</sub>O truncated nanocubes as trimodal image-guided near-infrared-III photothermal agents to combat multi-drug-resistant lung carcinoma. *ACS Nano*. 2021;15:14404–14418. doi:10.1021/acsnano.1c03784
7. Chen Z, Peng Y, Li Y, et al. Aptamer-dendrimer functionalized magnetic nano-octahedrons: theranostic drug/gene delivery platform for near-infrared/magnetic resonance imaging-guided magnetochemotherapy. *ACS Nano*. 2021;15(10):16683–16696. doi:10.1021/acsnano.1c06667
8. Zhang Z, Wang R, Luo R, et al. An activatable theranostic nanoprobe for dual-modal imaging-guided photodynamic therapy with self-reporting of sensitizer activation and therapeutic effect. *ACS Nano*. 2021;15(3):5366–5383. doi:10.1021/acsnano.0c10916
9. Gao S, Zhang L, Wang G, et al. Hybrid graphene/Au activatable theranostic agent for multimodalities imaging guided enhanced photothermal therapy. *Biomaterials*. 2016;79:36–45. doi:10.1016/j.biomaterials.2015.11.041
10. Qi C, He J, Fu L-H, et al. Tumor-specific activatable nanocarriers with gas-generation and signal amplification capabilities for tumor theranostics. *ACS Nano*. 2021;15(1):1627–1639. doi:10.1021/acsnano.0c09223
11. Gao Z, He T, Zhan P, et al. Polypeptide-based theranostics with tumor-microenvironment-activatable cascade reaction for chemo-ferroptosis combination therapy. *ACS Appl Mater Interfaces*. 2020;12(18):20271–20280. doi:10.1021/acsnano.0c03748
12. Li Y, Wu Y, Chen J, et al. A simple glutathione-responsive turn-on theranostic nanoparticle for dual-modal imaging and chemo-photothermal combination therapy. *Nano Lett*. 2019;19(8):5806–5817. doi:10.1021/acs.nanolett.9b02769
13. Wang Y, Jiang L, Zhang Y, et al. Fibronectin-targeting and cathepsin B-activatable theranostic nanoprobe for MR/fluorescence imaging and enhanced photodynamic therapy for triple negative breast cancer. *ACS Appl Mater Interfaces*. 2020;12(30):33564–33574. doi:10.1021/acsnano.0c10397
14. Yang C, Gao S, Song P, et al. Theranostic niosomes for efficient siRNA/microRNA delivery and activatable near-infrared fluorescent tracking of stem cells. *ACS Appl Mater Interfaces*. 2018;10(23):19494–19503. doi:10.1021/acsnano.8b05513
15. Cheng Y, Cheng A, Jia Y, et al. pH-Responsive multifunctional theranostic rapamycin-loaded nanoparticles for imaging and treatment of acute ischemic stroke. *ACS Appl Mater Interfaces*. 2021;13(48):56909–56922. doi:10.1021/acsnano.1c16530
16. Wu P, Wang X, Wang Z, et al. Light-activatable prodrug and AIEgen copolymer nanoparticle for dual-drug monitoring and combination therapy. *ACS Appl Mater Interfaces*. 2019;11(20):18691–18700. doi:10.1021/acsnano.9b02346
17. Wang Y, Du W, Zhang T, et al. A self-evaluating photothermal therapeutic nanoparticle. *ACS Nano*. 2020;14(8):9585–9593. doi:10.1021/acsnano.9b10144
18. Lv R, Wang Y, Liu J, et al. When a semiconductor utilized as an NIR laser-responsive photodynamic/photothermal theranostic agent integrates with upconversion nanoparticles. *ACS Biomater Sci Eng*. 2019;5(6):3100–3110. doi:10.1021/acsbomaterials.9b00438
19. Jia X, Pei M, Zhao X, et al. PEGylated oxidized alginate-DOX prodrug conjugate nanoparticles cross-linked with fluorescent carbon dots for tumor theranostics. *ACS Biomater Sci Eng*. 2016;2:1641–1648. doi:10.1021/acsbomaterials.6b00443
20. Miao Z-H, Wang H, Yang H, et al. Glucose-derived carbonaceous nanospheres for photoacoustic imaging and photothermal therapy. *ACS Appl Mater Interfaces*. 2016;8:15904–15910. doi:10.1021/acsnano.6b03652
21. Mangadlao JD, Wang X, McCleese C, et al. Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer. *ACS Nano*. 2018;12(4):3714–3725. doi:10.1021/acsnano.8b00940

22. Liu T, Jin R, Yuan P, et al. Intracellular enzyme-triggered assembly of amino acid-modified gold nanoparticles for accurate cancer therapy with multimode. *ACS Appl Mater Interfaces*. 2019;11(32):28621–28630. doi:10.1021/acsami.9b05943
23. Lee JE, Lee N, Kim T, et al. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. *Accounts Chem Res*. 2011;44(10):893–902. doi:10.1021/ar2000259
24. Wong RCH, Chow SYS, Zhao S, et al. pH-Responsive dimeric zinc (II) phthalocyanine in mesoporous silica nanoparticles as an activatable nanophotosensitizing system for photodynamic therapy. *ACS Appl Mater Interfaces*. 2017;9:23487–23496. doi:10.1021/acsami.7b06353
25. Yang W, Guo W, Le W, et al. Albumin-bioinspired Gd: CuSnanootheranostic agent for in vivo photoacoustic/magnetic resonance imaging-guided tumor-targeted photothermal therapy. *ACS Nano*. 2016;10:10245–10257. doi:10.1021/acs.nano.6b05760
26. Yang T, Wang Y, Ke HT, et al. Protein-nanoreactor-assisted synthesis of semiconductor nanocrystals for efficient cancer theranostics. *Adv Mater*. 2016;28(28):5923–5930. doi:10.1002/adma.201506119
27. Xu J, Zheng B, Zhang S, et al. Copper sulfide nanoparticle-redirected macrophages for adoptive transfer therapy of melanoma. *Adv Funct Mater*. 2021;31(11):2008022. doi:10.1002/adfm.202008022
28. Chu Z, Wang Z, Chen L, et al. Combining magnetic resonance imaging with photothermal therapy of CuS@BSA nanoparticles for cancer theranostics. *ACS Appl Nano Mater*. 2018;1(5):2332–2340. doi:10.1021/acsanm.8b00410
29. Shi H, Sun Y, Yan R, et al. Magnetic semiconductor Gd-doping CuS nanoparticles as activatable nanoprobe for bimodal imaging and targeted photothermal therapy of gastric tumors. *Nano Lett*. 2019;19(2):937–947. doi:10.1021/acs.nanolett.8b04179
30. Miyazaki M, Yuba E, Hayashi H, et al. Hyaluronic acid-based pH-sensitive polymer-modified liposomes for cell-specific intracellular drug delivery systems. *Bioconjugate Chem*. 2018;29:44–55. doi:10.1021/acs.bioconjchem.7b00551
31. Miyazaki M, Yuba E, Harada A, et al. Hyaluronic acid derivative-modified liposomes as pH-sensitive anticancer drug delivery system. *J Controlled Release*. 2015;213:73–74. doi:10.1016/j.jconrel.2015.05.122
32. Xu W, Qian J, Hou G, et al. Hyaluronic acid-functionalized gold nanorods with pH/NIR dual-responsive drug release for synergetic targeted photothermal chemotherapy of breast cancer. *ACS Appl Mater Interfaces*. 2017;9(42):36533–36547. doi:10.1021/acsami.7b08700
33. Zhao YQ, Zhang T, Duan SF, et al. CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy. *Nanomedicine*. 2014;10:1221–1230. doi:10.1016/j.nano.2014.02.015
34. Lapcik LJ, Lapcik L, De Smedt S, et al. Hyaluronan: preparation, structure, properties, and applications. *Chem Rev*. 1998;98:2663–2684. doi:10.1021/cr941199z
35. Ahmed HT, Patterson LH, Shnyder SD, et al. RGD-binding integrins in head and neck cancers. *Cancers*. 2017;9(12):56. doi:10.3390/cancers9060056
36. Dai X, Yu Y, Wei X, et al. Peptide conjugated CuS nanocomposites for NIR triggered ablation of pseudomonas aeruginosa biofilm. *ACS Applied Bio Materials*. 2019;2:1614–1622. doi:10.1021/acsabm.9b00033
37. Khadair A, Chen D, Patil Y, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. *J Controlled Release*. 2010;141(2):137–144. doi:10.1016/j.jconrel.2009.09.004
38. You J, Zhang GD, Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. *ACS Nano*. 2010;4(2):1033–1041. doi:10.1021/nn901181c
39. Wang J, Sun T, Yang M, et al. Hyaluronic acid-functionalized gold nanorods with pH/NIR dual-responsive drug release for synergetic targeted photothermal chemotherapy of breast cancer. *ACS Appl Mater Interfaces*. 2017;9:36533–36547.
40. Wang ZZ, Chen ZW, Liu Z, et al. A multi-stimuli responsive gold nanocage-hyaluronic platform for targeted photothermal and chemotherapy. *Biomaterials*. 2014;35:9678–9688. doi:10.1016/j.biomaterials.2014.08.013
41. Chen L-J, Sun S-K, Wang Y, et al. Activatable multifunctional persistent luminescence nanoparticle/copper sulfide nanoprobe for in vivo luminescence imaging-guided photothermal therapy. *ACS Appl Mater Interfaces*. 2016;8:32667–32674. doi:10.1021/acsami.6b10702
42. Medintz IL, Clapp AR, Mattoussi H, et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. *Nat Mater*. 2003;2(9):630–638. doi:10.1038/nmat961

## International Journal of Nanomedicine

Dovepress

### Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>